By Katherine Hamilton
Y-mAbs Therapeutics shares fell after it missed expectations with its revenue for the fourth quarter and estimate for 2025.
The stock declined 10% to $4.66 in pre-market trading Tuesday. Shares have lost half their value over the past three months.
The cancer treatment biopharmaceutical company posted a loss of $6.8 million, or 15 cents a share, for the three months ended Dec. 31, compared with $988 million, or 2 cents a share, the prior year.
Revenue increased 5% to $26.5 million, behind analysts' expectations of $26.7 million, according to FactSet.
Y-mAbs expects total revenue in 2025 to be $75 million to $90 million, while analysts polled by FactSet are anticipating $103.6 million.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 04, 2025 08:08 ET (13:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.